ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 618

Blood Lymphocytes Subtypes As Biomarkers for Early Identification of Optimal Responders to Anti-TNF Treatment in Rheumatoid Arthritis

Cristina Sobrino1, Borja Hernández-Breijo2, Israel Gañán-Nieto1, Carlota García-Hoz1, Victoria Navarro-Compán2, Ana Martínez2, Javier Bachiller1, María Gema Bonilla Hernán2, Dora Pascual-Salcedo2, Garbiñe Roy1, Mónica Vázquez1, Alejandro Balsa2, Luisa María Villar1, Chamaida Plasencia2 and Eulalia Rodríguez-Martín1, 1Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, 2Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, Biomarkers, lymphocytes and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: TNF inhibitors (TNFi) are the most common biological
agents used as disease-modifying treatment in rheumatoid arthritis (RA). Although these drugs have contributed to change the natural history of RA, approximately 30-50% of patients do not respond to this therapy. Early identification of optimal responders is crucial in the clinical setting. We aimed to study if baseline percentages of different leukocyte subsets in peripheral blood (PBMCs) can contribute to identify RA patients who will respond to TNFi.

Methods: This was a prospective bi-center pilot study including 50 RA patients under TNFi therapy. Clinical activity was assessed at baseline and 6 months of treatment by disease activity score 28 (DAS28), considering optimal responders if they reached remission at 6 months (DAS28≤2.6). PBMCs were obtained before treatment and different leukocyte subsets were evaluated by flow cytometry in a FACSCantoII instrument. All the analyses were adjusted by sex, age, concomitant methotrexate, baseline DAS28 and rheumatoid factor through a multivariate log-regression model (odds ratio; 95% CI).

Results: Optimal responders showed higher percentage of B cells (OR=1.28;95%; CI:1.06-1.54;p=0.011) and naive B cells (Bn; OR=1.50; 95%; CI:1.11-2.04;p=0.009) at baseline. We established cut-off values by ROC curves and analyzed the ability of both variables in predicting clinical response. Best results were obtained with Bn. Showing more than 2.55% of these cells associated with optimal response.

Conclusion: Our results suggest that basal Bn percentages may contribute to identify optimal responders to TNFi in RA. Although our data should be validated in larger cohorts.


Disclosure: C. Sobrino, None; B. Hernández-Breijo, None; I. Gañán-Nieto, None; C. García-Hoz, None; V. Navarro-Compán, None; A. Martínez, None; J. Bachiller, None; M. G. Bonilla Hernán, None; D. Pascual-Salcedo, None; G. Roy, None; M. Vázquez, None; A. Balsa, None; L. M. Villar, None; C. Plasencia, None; E. Rodríguez-Martín, None.

To cite this abstract in AMA style:

Sobrino C, Hernández-Breijo B, Gañán-Nieto I, García-Hoz C, Navarro-Compán V, Martínez A, Bachiller J, Bonilla Hernán MG, Pascual-Salcedo D, Roy G, Vázquez M, Balsa A, Villar LM, Plasencia C, Rodríguez-Martín E. Blood Lymphocytes Subtypes As Biomarkers for Early Identification of Optimal Responders to Anti-TNF Treatment in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/blood-lymphocytes-subtypes-as-biomarkers-for-early-identification-of-optimal-responders-to-anti-tnf-treatment-in-rheumatoid-arthritis/. Accessed August 12, 2022.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/blood-lymphocytes-subtypes-as-biomarkers-for-early-identification-of-optimal-responders-to-anti-tnf-treatment-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies